Mild to Moderate COVID-19 Withdrawn Phase 3 Trials for Adalimumab (DB00051)

Also known as: Mild, moderate Novel Coronavirus Infectious Disease (COVID-19) / Mild-to-moderate COVID-19

IndicationStatusPhase
DBCOND0131905 (Mild to Moderate COVID-19)Withdrawn3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04705844Study of Adalimumab or Placebo in Patients With Mild to Moderate COVID-19 (COMBAAT)Treatment